Deep Track Capital Portfolio
13F Holdings & Position Changes — Last filed Aug 14, 2026
13F Holdings & Position Changes — Last filed Aug 14, 2026
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Deep Track Capital is a $5B biotech-focused hedge fund managed by David Kroin. As of their latest 13F filing (Q2 2026), the fund holds 65 positions worth $6.7B. This quarter they initiated 12 new positions and exited 97. Their largest holding is GH ($509.1M).
Deep initiated 12 new positions and increased 27 this quarter. Portfolio grew +39.5% to $6.7B. 706 upcoming catalysts across holdings.
Portfolio Value (13F)
$6.7B
Holdings
65
Top 10 Concentration
40.5%
QoQ Change
+39.5%
Turnover
7.3%
Portfolio Value Trend
Be first to know when Deep Track Capital files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH | Guardant Health Inc. | Increased↑2Q | $509.1M | 7.57% | 10.4% | |
| 2 | IMVT | Immunovant Inc. | Decreased | $359.9M | 5.35% | 21.2% | |
| 3 | GPCR | Structure Therapeutics Inc. | Increased↑2Q | $254.4M | 3.78% | 11.7% | |
| 4 | PCVX | Vaxcyte Inc. | $250.0M | 3.72% | 10.1% | ||
| 5 | ALNY | Alnylam Pharmaceuticals Inc. | Increased | $248.3M | 3.69% | 4.8% | — |
| 6 | MANE | Veradermics, Inc. | Increased↑2Q | $245.9M | 3.66% | 14.7% | |
| 7 | TARS | Tarsus Pharmaceuticals Inc. | Increased↑6Q | $230.8M | 3.43% | 14.2% | |
| 8 | NUVL | Nuvalent Inc. | Increased↑2Q | $220.2M | 3.28% | 6.2% | |
| 9 | ALKS | Alkermes plc | Increased↑3Q | $209.6M | 3.12% | 12.2% | |
| 10 | OCUL | Ocular Therapeutix Inc. | $193.3M | 2.88% | 15.3% |
Share changes reflect active decisions. Value changes include price moves.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
See all 65 holdings (you're viewing the top 10), plus 8 quarters of position history.
No charge for 14 days · Cancel anytime
Deep Track Capital held 65 biotech stocks in their 13F portfolio this quarter. Their top positions include GH, IMVT, GPCR, PCVX, ALNY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Deep Track Capital's tracked biotech portfolio is worth $6.7B across 65 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
Deep Track Capital initiated 12 new positions this quarter, including COAG, UTHR, ALT, WGSWW, HROW and 7 more. They also increased 27 existing positions.
Deep Track Capital fully exited 97 positions this quarter, including ALEC, FATE, INSM, ALLK, PEPG and 92 more. They also trimmed 15 existing positions.
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial